(Stroke. 1996;27:2120-2123.)
© 1996 American Heart Association, Inc.
Articles |
PPBP [4-Phenyl-1-(4-phenylbutyl) Piperidine] Decreases Brain Injury After Transient Focal Ischemia in Rats
the Department of Anesthesiology and Critical Care Medicine, The Johns Hopkins Medical Institutions (H.T., J.R.K., R.C.K., R.J.T.), and the Neuroimaging and Drug Action Section, Division of Intramural Research, National Institute on Drug Abuse (K.H., E.D.L.), Baltimore, Md.
Background and Purpose We tested the hypothesis that intravenous administration of the potent 
-receptor ligand 4-phenyl-1-(4-phenylbutyl) piperidine (PPBP) during transient focal ischemia would decrease postischemic brain infarction volume in rats.
Methods Rats underwent intravascular focal ischemia for 2 hours followed by 22 hours of reperfusion. Halothane anesthesia was used only during initiation and cessation of ischemia. Rats received saline (n=10) or 1 µmol/kg per hour PPBP (n=10) by continuous intravenous infusion starting 1 hour after the initiation of ischemia and continuing through 22 hours of reperfusion.
Results There was no difference between groups in blood pressure, arterial blood gas values, and body temperature. Triphenyltetrazolium-determined infarction volume of ipsilateral cerebral cortex (saline, 39±6%; PPBP, 21±7% of ipsilateral hemisphere; mean±SEM) and striatum (saline, 68±6%; PPBP, 33±8% of ipsilateral striatum) was smaller in rats treated with PPBP than in rats treated with saline.
Conclusions These data indicate that -receptors may play an important role in the mechanism of injury both in cortex and striatum after 2 hours of transient focal ischemia in rats. Because PPBP afforded protection when administered at the end of ischemia and during reperfusion, -receptors may influence the progression of injury in ischemic border regions.
Editorial Comment
Department of Cardiovascular Pharmacology, SmithKline Beecham Pharmaceuticals, King of Prussia, Pa
This article has been cited by other articles:
 |
|
 |
|
  S. Yang, N. J. Alkayed, P. D. Hurn, and J. R. Kirsch Cyclic Adenosine Monophosphate Response Element-Binding Protein Phosphorylation and Neuroprotection by 4-Phenyl-1-(4-Phenylbutyl) Piperidine (PPBP) Anesth. Analg., March 1, 2009; 108(3): 964 - 970. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Yang, A. Bhardwaj, J. Cheng, N. J. Alkayed, P. D. Hurn, and J. R. Kirsch Sigma Receptor Agonists Provide Neuroprotection In Vitro by Preserving bcl-2 Anesth. Analg., May 1, 2007; 104(5): 1179 - 1184. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Katnik, W. R. Guerrero, K. R. Pennypacker, Y. Herrera, and J. Cuevas Sigma-1 Receptor Activation Prevents Intracellular Calcium Dysregulation in Cortical Neurons during in Vitro Ischemia J. Pharmacol. Exp. Ther., December 1, 2006; 319(3): 1355 - 1365. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Vagnerova, P. D. Hurn, A. Bhardwaj, and J. R. Kirsch Sigma 1 receptor agonists act as neuroprotective drugs through inhibition of inducible nitric oxide synthase. Anesth. Analg., August 1, 2006; 103(2): 430 - 4, table of contents. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Goyagi, A. Bhardwaj, R. C. Koehler, R. J. Traystman, P. D. Hurn, and J. R. Kirsch Potent {sigma}1-Receptor Ligand 4-Phenyl-1-(4-Phenylbutyl) Piperidine Provides Ischemic Neuroprotection Without Altering Dopamine Accumulation In Vivo in Rats Anesth. Analg., February 1, 2003; 96(2): 532 - 538. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. R. Anderson and R. D. Andrew Spreading Depression: Imaging and Blockade in the Rat Neocortical Brain Slice J Neurophysiol, November 1, 2002; 88(5): 2713 - 2725. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Bhardwaj, A. F. Castro III, N. J. Alkayed, P. D. Hurn, and J. R. Kirsch Anesthetic Choice of Halothane Versus Propofol: Impact on Experimental Perioperative Stroke Stroke, August 1, 2001; 32(8): 1920 - 1925. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Goyagi, S. Goto, A. Bhardwaj, V. L. Dawson, P. D. Hurn, and J. R. Kirsch Neuroprotective Effect of {{sigma}}1-Receptor Ligand 4-Phenyl-1-(4-Phenylbutyl) Piperidine (PPBP) Is Linked to Reduced Neuronal Nitric Oxide Production Stroke, July 1, 2001; 32(7): 1613 - 1620. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Bhardwaj, I. Harukuni, S. J. Murphy, N. J. Alkayed, B. J. Crain, R. C. Koehler, P. D. Hurn, R. J. Traystman, and J. C. Watson Hypertonic Saline Worsens Infarct Volume After Transient Focal Ischemia in Rats Editorial Comment Stroke, July 1, 2000; 31(7): 1694 - 1701. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Harukuni, A. Bhardwaj, A. B. Shaivitz, A. C. DeVries, E. D. London, P. D. Hurn, R. J. Traystman, J. R. Kirsch, and F. M. Faraci {sigma}1-Receptor Ligand 4-Phenyl-1-(4-Phenylbutyl)-Piperidine Affords Neuroprotection From Focal Ischemia With Prolonged Reperfusion • Editorial Comment Stroke, April 1, 2000; 31(4): 976 - 982. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. J. Toung, A. Bhardwaj, V. L. Dawson, T. M. Dawson, R. J. Traystman, P. D. Hurn, and P. H. Chan Neuroprotective FK506 Does Not Alter In Vivo Nitric Oxide Production During Ischemia and Early Reperfusion in Rats • Editorial Comment Stroke, June 1, 1999; 30(6): 1279 - 1285. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Bhardwaj, M. Sawada, E. D. London, R. C. Koehler, R. J. Traystman, J. R. Kirsch, and F. M. Faraci Potent {varsigma}1-Receptor Ligand 4-Phenyl-1-(4-Phenylbutyl) Piperidine Modulates Basal and N-Methyl-D-Aspartate–Evoked Nitric Oxide Production In Vivo • Editorial Comment Stroke, November 1, 1998; 29(11): 2404 - 2411. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. J. Alkayed, I. Harukuni, A. S. Kimes, E. D. London, R. J. Traystman, P. D. Hurn, and P. A. Grady Gender-Linked Brain Injury in Experimental Stroke • Editorial Comment Stroke, January 1, 1998; 29(1): 159 - 166. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. R. Whittemore, V. I. Ilyin, and R. M. Woodward Antagonism of N-Methyl-D-Aspartate Receptors by sigma Site Ligands: Potency, Subtype-Selectivity and Mechanisms of Inhibition J. Pharmacol. Exp. Ther., July 1, 1997; 282(1): 326 - 338. [Abstract] [Full Text]
|
|